Last reviewed · How we verify
NCT03963362
The Pharmacokinetics of GLA5PR Tablet According to the Renal Function
Phase 1 trial testing GLA5PR tablet 75 mg in Neuropathic Pain in 24 participants. Status unknown.
31 December 2020
Quick facts
| Lead sponsor | GL Pharm Tech Corporation |
|---|---|
| Phase | Phase 1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 24 |
| Start date | 17 September 2019 |
| Primary completion | 31 December 2020 |
| Estimated completion | 30 June 2021 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- GLA5PR tablet 75 mg — full drug profile →
- GLA5PR tablet 150 mg — full drug profile →
Conditions studied
- Neuropathic Pain — all drugs for Neuropathic Pain →
Sponsor
GL Pharm Tech Corporation — full company profile →
Who can join
Adults 19 to 64, any sex, with Neuropathic Pain. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evauate pharmacokinetics of GLA5PR tablet according to the renal function
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03963362
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Neuropathic Pain
Currently open trials in the same condition.
- NCT07493213 — USG-Guided Shoulder Injections in Frozen Shoulder · NA · recruiting
- NCT07493226 — Efficacy of Chemically Distinct Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) and Pain Phenotypes in Adhesive Capsulitis · NA · recruiting
- NCT06398847 — Virtual Reality (VR) Self-Hypnosis Software · NA · recruiting
- NCT07487610 — Relationship Between Neuropathic Pain and Geriatric Assessment Parameters in Patients Aged 80 Years and Older · recruiting
- NCT07436806 — SPS Block vs. Surgical Intercostal Block for Chronic Pain After Thoracoscopic Surgery · NA · recruiting
Other GL Pharm Tech Corporation trials
Trials by the same sponsor.
- NCT04679883 — Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of GLH8NDE in Patients With Dry Eye Disease · Phase 2 · unknown
- NCT04104997 — A Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of GLH8NDE After Single and Mu · Phase 1 · completed
- NCT03927170 — Pharmacokinetic Characteristics of GLH1SM Extended Release Tablets in Healthy Volunteers(Fed) · Phase 1 · completed
- NCT03851341 — Pharmacokinetic Characteristics of GLH1SM Extended Release Tablets in Healthy Volunteers · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03963362 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by GL Pharm Tech Corporation
- Last refreshed: 23 July 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03963362.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing